Retinal Vein Occlusion and Diabetic Macular Oedema Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 18 years or older
- People who have been diagnosed with diabetic retinopathy, with or without swelling in the central part of the retina (called macular edema)
- People whose condition means that eye injection treatment (called anti-VEGF therapy) is recommended under current medical guidelines
- People who are able to give written consent to participate
Who may not be able to join:
- People who have received eye injection treatments (anti-VEGF or steroid injections) in the eye being studied within the past 5 months
- People who have had any surgery inside the eye, including cataract surgery, within the past 3 months
- People who have had laser treatment on the retina of the eye being studied within the past 3 months
- People who have other eye, retina, or macular conditions that could affect scan results or vision quality — for example, age-related macular degeneration or blocked blood vessels in the retina
- People who have a detached retina, scar tissue forming over the retina, or abnormal pulling between the gel inside the eye and the retina
- People whose eye has significant cloudiness or bleeding inside that would make detailed eye scans unreliable
- People with poorly controlled glaucoma, meaning high pressure inside the eye being studied
- People with active inflammation inside the eye
- People with a suspected active infection in either eye
- People who have had a fever-related illness within the week before the first injection
- People with a significant medical condition, metabolic disorder, unusual test results, or physical findings that, in the trial doctor's judgement, could make the study treatments unsafe or make results difficult to interpret
- Women who are pregnant, breastfeeding, or planning to become pregnant within the next approximately 100 weeks
- People with a known allergy or sensitivity to either of the study medications (faricimab or biosimilar ranibizumab) or any of their ingredients
- People currently participating in another clinical trial that could affect this study's results
- People who are unlikely to be able to follow the study procedures or attend required follow-up visits
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +385981962588
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Comparison of OCT and OCTA biomarkers associated with early anatomical treatment response to faricimab and biosimilar ranibizumab
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.